Cartesian Therapeutics (SELB) Revenue & Revenue Breakdown
Cartesian Therapeutics Revenue Highlights
Latest Revenue (Q)
$6.55M
Main Segment (Y)
Grant
Main Geography (Y)
Grant
Cartesian Therapeutics Revenue by Period
Cartesian Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $110.78M | 30.21% |
| 2021-12-31 | $85.08M | 412.60% |
| 2020-12-31 | $16.60M | 148.57% |
| 2019-12-31 | $6.68M | 639.42% |
| 2018-12-31 | $903.00K | 336.23% |
| 2017-12-31 | $207.00K | -97.44% |
| 2016-12-31 | $8.08M | 34.47% |
| 2015-12-31 | $6.01M | 97.73% |
| 2014-12-31 | $3.04M | - |
Cartesian Therapeutics generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Cartesian Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2023-09-30 | $6.55M | 24.80% |
| 2023-06-30 | $5.25M | -11.60% |
| 2023-03-31 | $5.94M | -64.64% |
| 2022-12-31 | $16.80M | -18.90% |
| 2022-09-30 | $20.71M | -47.27% |
| 2022-06-30 | $39.27M | 15.51% |
| 2022-03-31 | $34.00M | 13.57% |
| 2021-12-31 | $29.94M | 22.56% |
| 2021-09-30 | $24.43M | 24.23% |
| 2021-06-30 | $19.66M | 77.95% |
| 2021-03-31 | $11.05M | -7.54% |
| 2020-12-31 | $11.95M | 157.23% |
| 2020-09-30 | $4.65M | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | -100.00% |
| 2019-12-31 | $6.65M | 100.00% |
| 2019-09-30 | - | -100.00% |
| 2019-06-30 | $13.00K | 30.00% |
| 2019-03-31 | $10.00K | -98.89% |
| 2018-12-31 | $903.00K | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | -100.00% |
| 2017-12-31 | $17.00K | -37.04% |
| 2017-09-30 | $27.00K | 3.85% |
| 2017-06-30 | $26.00K | -81.02% |
| 2017-03-31 | $137.00K | -95.32% |
| 2016-12-31 | $2.93M | 179.58% |
| 2016-09-30 | $1.05M | -48.04% |
| 2016-06-30 | $2.02M | -3.40% |
| 2016-03-31 | $2.09M | -2.16% |
| 2015-12-31 | $2.13M | 32.79% |
| 2015-09-30 | $1.61M | 30.02% |
| 2015-06-30 | $1.24M | 19.54% |
| 2015-03-31 | $1.03M | - |
Cartesian Therapeutics generated $6.55M in revenue during Q3 2023, up 24.80% compared to the previous quarter, and up 16.68% compared to the same period a year ago.
Cartesian Therapeutics Revenue Breakdown
Cartesian Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 19 |
|---|---|
| Grant | $100.00K |
Cartesian Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 19: Grant (100.00%).
Quarterly Revenue by Product
| Product/Service | Sep 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|
| Grant | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K |
Cartesian Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 20: Grant (100.00%).
Cartesian Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 19 |
|---|---|
| Grant | $100.00K |
Cartesian Therapeutics's latest annual revenue breakdown by geography, as of Dec 19: Grant (100.00%).
Quarterly Revenue by Country
| Country | Mar 20 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|
| Grant | $100.00K | $100.00K | $100.00K | $100.00K |
Cartesian Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 20: Grant (100.00%).
Cartesian Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RIGL | Rigel Pharmaceuticals | $116.88M | $36.84M |
| CDTX | Cidara Therapeutics | $63.91M | $8.46M |
| FBIO | Fortress Biotech | $59.66M | $13.03M |
| IMMP | Immutep | $3.51M | $2.11M |
| GMDA | Gamida Cell | $1.78M | $890.00K |
| GERN | Geron | $237.00K | $304.00K |
| CKPT | Checkpoint Therapeutics | $103.00K | $41.00K |
| EYEN | Eyenovia | $3.79K | $4.99K |
| CRVS | Corvus Pharmaceuticals | - | - |
| MBIO | Mustang Bio | - | - |
| RVPH | Reviva Pharmaceuticals | - | - |
| SELB | Cartesian Therapeutics | - | $6.55M |
| CGTX | Cognition Therapeutics | - | - |
| KOD | Kodiak Sciences | - | - |
| RNAZ | TransCode Therapeutics | - | - |
SELB Revenue FAQ
What is Cartesian Therapeutics’s yearly revenue?
Cartesian Therapeutics's yearly revenue for 2023 was $0, representing a decrease of -100.00% compared to 2022. The company's yearly revenue for 2022 was $110.78M, representing an increase of 30.21% compared to 2021. SELB's yearly revenue for 2021 was $85.08M, representing an increase of 412.60% compared to 2020.
What is Cartesian Therapeutics’s quarterly revenue?
Cartesian Therapeutics's quarterly revenue for Q3 2023 was $6.55M, a 24.80% increase from the previous quarter (Q2 2023), and a -68.37% decrease year-over-year (Q3 2022). The company's quarterly revenue for Q2 2023 was $5.25M, a -11.60% decrease from the previous quarter (Q1 2023), and a -86.63% decrease year-over-year (Q2 2022). SELB's quarterly revenue for Q1 2023 was $5.94M, a -64.64% decrease from the previous quarter (Q4 2022), and a -82.53% decrease year-over-year (Q1 2022).
What is Cartesian Therapeutics’s revenue growth rate?
Cartesian Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was -100.00%.
What are Cartesian Therapeutics’s revenue streams?
Cartesian Therapeutics's revenue streams in c 19 are Grant
What is Cartesian Therapeutics’s main source of revenue?
For the fiscal year ending Dec 19, the largest source of revenue of Cartesian Therapeutics was Grant. This segment made a revenue of $100K, representing 100.00% of the company's total revenue.